NEW DELHI : Two doses of Bharat Biotech's Covaxin result in 50% effectiveness against symptomatic covid-19, as per the first real-world assessment of the India-developed vaccine, published in The Lancet Infectious Diseases journal.
The study was conducted during India’s second covid-19 surge in a high-exposure population (healthcare workers). The researchers assessed 2,714 hospital workers from the All India Institute of Medical Sciences (AIIMS) in Delhi, India, from April 15 to May 15, 2021, who were symptomatic and underwent RT-PCR testing for covid-19.
The delta variant was the dominant strain in India during the study period, accounting for approximately 80% of all confirmed covid-19 cases. “Our study offers a more complete picture